Logo

Orion Genomics, Wash U to Co-develop Cancer Tests Based on Methylated DNA

Aug 09, 2005

NEW YORK, Aug. 9 (GenomeWeb News) - Orion Genomics is collaborating with researchers at WashingtonUniversityin St. Louisto discover diagnostic cancer biomarkers, the St. Louis-based company said today.

 

In several collaborations, scientists at Orion and WashingtonUniversitywill study common cancers, including lung, breast, cervical, prostate, and ovarian cancer, to find DNA methylation-based biomarkers of cancer and those that indicate how a cancer will respond to certain therapies.

 

Orion plans to develop tests that detect trace amounts of methylated tumor DNA in tissues such as blood serum, biopsies, and cell scraps, and expects to market them within three years.

Breaking News
The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.